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Abstract
Background: Postoperative pulmonary complications (PPC) and peri-operative myocardial infarction (MI) have a
significant impact on the long-term mortality of surgical patients. Patients undergoing one-lung ventilation (OLV)
for surgery are at a high risk of developing these complications. These complications could be associated with
intensive care unit (ICU) admissions and longer hospital stay with associated resource and economic burden.
Simvastatin, a HMG-CoA reductase enzyme inhibitor has been shown to have pleiotropic anti-inflammatory effects
as well as being endothelial protective. The benefits of statins have been shown in various observational studies
and in small proof-of-concept studies. There is an urgent need for a well-designed, large clinical trial powered to
detect clinical outcomes. The Prevention HARP 2 trial will test the hypothesis ‘simvastatin 80 mg when compared
to placebo will reduce cardiac and pulmonary complications in patients undergoing elective oesophagectomy,
lobectomy or pneumonectomy’.
Methods/design: The Prevention HARP 2 trial is a UK multi-centre, randomised, double-blind, placebo-controlled
trial. Adult patients undergoing elective oesophagectomy, lobectomy or pneumonectomy will be eligible. Patients
who are already on statins will be excluded from this trial. Patients will be randomised to receive simvastatin 80 mg
or matched placebo for 4 days pre surgery and for up to 7 days post surgery. The primary outcome is a composite
outcome of PPC and MI within 7 days post surgery. Various secondary outcome measures including clinical
outcomes, safety outcomes and health economic outcomes will be collected. The study aims to recruit 452 patients
in total across 12 UK sites.
Discussion: The results of the Prevention HARP 2 trial should add to our understanding of the benefits of peri-
operative statins and influence clinical decision-making. Analysis of blood and urine samples from the patients will
provide insight into the mechanism of simvastatin action.
Trial registration: International Standard Randomised Controlled Trials registry, ID: ISRCTN48095567. Registered on
11 November 2016.
Keywords: Simvastatin, Post-operative pulmonary complication, Post-operative myocardial infarction, Acute
respiratory distress syndrome, One-lung ventilation, Oesophagectomy, Lobectomy, Pneumonectomy
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Background
One-lung ventilation (OLV) is an anaesthetic technique
used commonly in surgeries like oesophagectomy, lobec-
tomy and pneumonectomy. These surgeries are associ-
ated with high rates of post-operative pulmonary
complications (PPC) with rates between 13 and 43% in
the literature [1–3]. The myocardial infarction (MI), in-
cluding myocardial infarction after non-cardiac surgery
(MINS), rate is approximately 8% with a higher rate of
up to 16% in patients undergoing thoracotomy for
non-cardiac surgery [4, 5]. Post-operative pulmonary
complications and MI are common and devastating clin-
ical conditions with high morbidity and mortality, inten-
sive care unit (ICU) admissions and length of stay [6–8].
Cardiac and respiratory complications have both immedi-
ate and long-standing resource implications that include
an increase in ventilator usage, critical care support and
on-going rehabilitation needs in the community post dis-
charge [3, 7, 9]. The occurrence of post-operative compli-
cations within 30 days is a strong determinant of both
short-term and long-term mortality [10].
This highlights the need for multi-centre, randomised,
placebo-controlled trials of therapies aimed at reducing
the incidence of PPC, acute respiratory distress syn-
drome (ARDS) and MI to improve patient outcomes.
Statins can modulate mechanisms important in the
pathogenesis of pulmonary and cardiac complications
Statins have significant immunomodulatory properties in
addition to reducing plasma cholesterol levels. Pulmonary
complications, including ARDS, are inflammatory condi-
tions driven by inflammatory cells such as neutrophils
[11] and macrophages [12]. Hydroxy-methylglutaryl coen-
zyme A reductase (HMG-CoA) inhibition with statins is a
promising new therapeutic option since statins modulate
a number of the underlying processes described in the de-
velopment of pulmonary and cardiac complications.
Statins have diverse anti-inflammatory properties [12] that
reduce pulmonary inflammation and improve atheroscler-
otic plaque stability [13]. In an inhaled lipopolysacchar-
ide (LPS) model of pulmonary inflammation and
injury, simvastatin 80 mg significantly reduced pul-
monary neutrophil infiltrate and both cytokines and
tissue-degrading proteases in bronchoalveolar lavage,
compared with placebo [12].
One-lung ventilation leading to pulmonary inflamma-
tion is one of the putative mechanisms driving PPC rates
and atherosclerotic plaque instability is a key mechanism
for post-operative MI. Simvastatin has been shown to be
beneficial in reducing pulmonary inflammation and in-
jury in human in-vivo models of pulmonary injury [12]
as well as in a single-centre trial in patients undergoing
oesophagectomy [14] while conferring protection against
MI by increasing plaque stability, improving endothelial
function [15]. There is a strong biological rationale for
using simvastatin to reduce the incidence of
post-operative inflammatory complications, such as
PPC, ARDS and MI, that form the composite primary
outcome for this trial.
Studies support a multi-centre clinical trial of statin to
prevent pulmonary and cardiac complications
A recent meta-analysis, which included more than 2000
patients undergoing surgery for cardiac, non-cardiac and
vascular indications, concluded that pre-operative statin
use was associated with a significant reduction in
post-operative MI, atrial fibrillation (AF) and length of
hospital stay [16]. Peri-operative statin use has been
shown to reduce mortality, cardiovascular and respira-
tory complications in a recent retrospective database
analysis involving more than 48,000 propensity-matched
pairs of patients undergoing non-cardiac surgery [17].
Simvastatin was the most frequently used statin in most
of the studies. In cardiovascular surgery patients, the
addition of a statin pre-operatively significantly reduced
mortality, AF and MI [18] while in a single-centre pro-
spective observational study of patients undergoing gen-
eral non-cardiac surgery, non-cardiac complications,
including PPC, were reduced [19]. Statins also reduced
PPC in patients undergoing pulmonary resection who
were randomised to receive atorvastatin 40mg or placebo
prior to surgery [20] but this was a single-centre, under-
powered study. Similarly, simvastatin 80mg administered
pre-operatively for 4 days and post-operatively for 7 days
significantly reduced pulmonary inflammation in patients
undergoing OLV for oesophagectomy [14].
While the above studies demonstrate potential benefit
for the use of statins as an anti-inflammatory therapy, in
a recently concluded multi-centre trial in patients with
ARDS, simvastatin 80 mg did not show any benefit in
mortality or ventilatory-free days of organ dysfunction
[21] but this is likely secondary to patient heterogeneity
where a post-hoc analysis suggests benefit in patients
with a hyper-inflammatory phenotype [22]. Similarly, a
large multi-centre study investigating the benefit of
peri-operative atorvastatin and acute kidney injury fol-
lowing cardiac surgery was stopped early due to futility
[23]. The LOAD trial, which is a peri-operative trial of
atorvastatin administered prior to surgery and continued
for 7 days post surgery in non-cardiac surgery, did not
show any reduction in the composite outcome of mor-
tality, MI and MINS. There was a 40% non-significant
reduction in the primary outcomes in a landmark sensi-
tivity analysis. The lack of effect is possibly due to the
short duration of pre-operative statin exposure where an
increase by even a day of statin therapy is associated
with relative reduction in post-operative MI [24].
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These studies demonstrate the conflicting evidence
but potential benefits of statins in preventing pulmonary
and cardiac complications post surgery, the biological
rationale for these effects and the urgent need for an ad-
equately powered multi-centre trial.
Safety of peri-operative statin use
Statins have been proven to be a well-tolerated class of
drugs. Simvastatin 80mg is within the licensed therapeutic
range for the treatment of hypercholesterolaemia. In a
study where 2265 patients following an acute coronary syn-
drome were randomised to receive simvastatin 80mg, my-
opathy (creatine kinase) (creatine kinase (CK) > 10 times
the upper limit of normal (ULN) associated with muscle
symptoms) occurred in only 0.4% and rhabdomyolysis
(CK > 10,000 units/L with or without muscle symptoms) in
0.13% [25]. Importantly in this study, follow-up was only at
months 1, 4 and 8 and every 4months thereafter for up to
24months until trial completion. The data from our
proof-of-concept study reassuringly found that simvastatin
80mg was well tolerated and not associated with increased
adverse events (AEs) compared to placebo. There was no
difference in CK levels or numbers of patients with a CK >
10 times the ULN between the groups. There were
no differences in serum creatinine (SrCr) levels, liver
transaminases (alanine transaminase (ALT) and aspar-
tate aminotransferase (AST)) between the groups. No
drug-related serious adverse events (SAEs) occurred
during the study. Furthermore, the incidence of clin-
ical adverse outcomes, such as ARDS, infections and
arrhythmias, was less in the simvastatin-treated group
when compared to the placebo group but this study
was not powered to detect clinical outcomes [14].
Hypothesis
This trial will test the hypothesis that simvastatin 80 mg
reduces cardiac and pulmonary complications, when
compared to placebo, in patients undergoing elective
oesophagectomy, lobectomy or pneumonectomy.
Methods/design
Ethical approval for this trial was provided by South
Central – Berkshire Research Ethics Committee. The
International Standard Randomised Controlled Trial
Registry number for trial registration is ISRCTN48095567.
The sponsor organisation for the trial is the Belfast Health
and Social Care Trust (BHSCT). The trial is coordinated
by the Northern Ireland Clinical Trials Unit (NICTU;
www.nictu.hscni.net). The trial is funded by a National In-
stitute for Health Research (NIHR) Clinician Scientist Fel-
lowship administered through the Research and
Development Office of Northern Ireland Public Health
Agency (Funder reference no. CDV/5137/15). The trial
will be carried out in accordance with the Medical
Research Council Good Clinical Practice Guidelines, ap-
plicable UK legislation and the standard operating proce-
dures (SOPs) of the NICTU. This manuscript was written
in concordance with the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) guidelines
[26]. The trial will be reported in line with the Consoli-
dated Standards of Reporting Trials (CONSORT) 2010
guidelines [27].
Outcome measures
Primary outcome
The primary outcome measure is a composite endpoint
of the incidence of ARDS, defined according to the
Berlin definition [28], PPC as defined by the Melbourne
Group Scale (MGS) [29] and MI as defined by ischaemic
chest pain, electrocardiograph changes and a raise in
plasma troponin and also by myocardial ischaemia post
non-cardiac surgery (MINS) criteria [4] during the first
7 days post-operatively. These endpoints were chosen
based on their effect on short-term and long-term out-
comes and a biological rationale for simvastatin in
modulating these endpoints.
Secondary outcomes
Secondary outcomes include clinical outcomes, safety
and health economic outcomes (health-related quality of
life (HRQoL) and costs).
Clinical outcomes Mortality at day 28 and day 90,
ventilator-free days [30], defined as the number of days in
the first 28 days following surgery that a patient is free
from ventilator assistance, for greater than 48 h; ARDS,
PPC and MI within 28 days of surgery or hospital dis-
charge if earlier; AF within 28 days of surgery or hospital
discharge if earlier, venous thromboembolism [31] within
28 days of surgery or hospital discharge if earlier and the
incidence and nature of any surgical complications.
Safety Creatine kinase > 10 times the ULN (day 0, day 3
and day 7 post surgery) of the local laboratory range;
ALT/AST > 5 times the ULN (day 0, day 3 and day 7 post
surgery) of the local laboratory range; acute kidney injury
defined according to Kidney Disease Improving Global
Outcomes guidelines (using change from baseline SrCr)
within 7 days of surgery; SAEs, AEs and occurrence of
suspected unexpected serious adverse reactions (SUSARs).
Health economic outcomes HRQoL as measured using
the EuroQoL-5 Dimension Questionnaire (5-level ver-
sion) (EQ-5D-5 L) [32] at baseline and at 90 days post
surgery; health and social care resource use: length of
ICU stay (level-3 care), length of high-dependency unit
stay (level-2 care), length of hospital stay, health service
contacts up to 90 days post surgery.
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Exploratory outcomes Plasma and urine samples will
be collected to understand the mechanism of simvastatin
action by measuring markers of inflammation and cellu-
lar injury. Biomarkers of systemic inflammation (TNFα,
IL-8, IL-6, IL-1β) and epithelial and endothelial injury
(von-Willebrand factor, surfactant protein-D, receptor
for advanced glycation end product) and a marker of
systemic endothelial dysfunction (urine albumin to cre-
atinine ratio) and neutrophil activation (myeloperoxi-
dase, neutrophil elastase) will be measured.
Eligibility criteria
Patients’ eligibility to take part in the trial will be con-
firmed by medically qualified member of the research
team when they fulfil the following inclusion and exclu-
sion criteria.
Inclusion criteria:
1. Adult patients ≥ 18 years of age undergoing OLV for
elective oesophagectomy, lobectomy or
pneumonectomy
2. Female subjects must be surgically sterile, or be
postmenopausal, or must agree to use effective
contraception during the period of the trial and for
at least 30 days after completion of treatment. A
pregnancy test, measured by urine human
chorionic gonadotropin, in women of child-
bearing potential will be performed at the pre-
operative assessment clinic
Exclusion criteria:
1. Age < 18 years
2. Creatinine kinase ULN (CK) > 5 times ULN range
of the local laboratory range
3. Known active liver disease (Child-Pugh score > 11),
or abnormal liver function tests: transaminases
(AST or ALT) ULN > 3 times ULN range (ULN) of
the local laboratory range
4. Renal impairment (calculated SrCr clearance less
than 30 mL/min)
5. Inability to take medication enterally pre-operatively
6. Subject-reported lactose intolerance
7. Participation in other intervention trials within 30 days
8. Current treatment with statins
9. Known hypersensitivity to the study medication
10. Previous adverse reaction (AR) to statins
11. Concomitant use of fibrates or other lipid-lowering
therapy
12. Concomitant use of itraconazole, ketoconazole,
posaconazole, voriconazole, erythromycin,
clarithromycin, telithromycin, HIV-protease inhibi-
tors, boceprevir, telaprevir, nefazodone, cobicistat,
cyclosporine, danazol, amiodarone, amlodipine, ver-
apamil or diltiazem, fusidic acid and niacin
13. Patients must be able to understand and give signed
and dated informed consent indicating that they
understand all the pertinent aspects of the trial
prior to enrolment
14. Currently pregnant or lactating
Sample size calculation
The incidence of PPC varies, ranging from 13 to 43% in
the literature [2, 3, 33]. The significant variation is at
least partly explained by varying criteria used to define
PPC. The incidence of ARDS in our proof-of-concept
study was 25% in the placebo group [14]. The incidence
of MI ranges from 5 to 8% based on the MINS criteria
[11, 30]. In patients undergoing thoracic surgery, a re-
cent study has demonstrated a MINS incidence of 16%
[8]. For the sample size calculation, the control group
event rate is expected to be approximately 25% with a
conservative estimate of 15% PPC (including ARDS) and
10% MI by day 7 post surgery.
There are no prospective randomised controlled trials in
surgeries utilising the OLV technique in patients to pre-
dict the size of the treatment effect on preventing both
cardiac and respiratory complications post surgery. In a
single-centre study of atorvastatin in patients undergoing
elective pulmonary resection, there was a 50% absolute re-
duction in PPC rate in the atorvastatin-treated group [20].
In patients undergoing vascular surgery, fluvastatin pre
treatment reduced the risk of MI from 20 to 10% [13]. In
a randomised, placebo-controlled trial, simvastatin pre
treatment was associated with a 37% absolute reduc-
tion in troponin release [15]. To inform the likely loss
to follow-up, previous randomised controlled trials in
oesophagectomy patients have experienced a 1–2%
loss-to-follow-up rate over 7 days [34, 35].
The preliminary sample size of 203 is based on a
two-group chi-square test with 50% relative reduction
in incidence of the composite endpoint from a
predicted rate of 25% in the control group with 90%
power of detecting this difference at p = 0.05. The
inclusion of a 10% dropout rate gives an overall sam-
ple size of 226 per arm or 452 in total. Our
proof-of-concept study indicates that 70% of patients
would fulfil the criteria for enrolment. In a recent
trial of statins in patients with ARDS, the exclusion
rate due to prior statin use was 30% with a further
10% refusing assent/consent [36].
The planned recruitment from 12 UK sites with a con-
servative recruitment of 50% of eligible patients, which
includes a 10% failure to progress to surgery, will enable
completion of recruitment in 30months at the rate of 15
patients/month (Fig. 1: CONSORT diagram).
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Trial conduct
Approach to patients and obtaining informed consent
The study will be conducted in hospitals in the UK. An
up-to-date list of study sites can be obtained from the
NICTU. Patients will be identified through upper
gastrointestinal/thoracic oncology multidisciplinary
meetings and waiting list offices. Eligible patients will
be invited to participate by the research team. If agree-
able, written informed consent will be obtained, follow-
ing a face-to-face discussion about the study. All the
members of the research team will undergo Good Clin-
ical Practice (GCP) training, training on study-related
documents and on SOPs.
No financial incentive has been planned for trial inves-
tigators or participants. No competing interest disclosed
by the principal investigators (PIs). The study interven-
tions are detailed in Fig. 2 and in Additional file 1.
Sequence generation
Eligible participants will be allocated to intervention or
placebo using an automated randomisation system
(Sealed Envelopes). After obtaining informed consent,
patients will be randomised on a 1:1 allocation ratio
pre-operatively, stratified by centre.
Allocation concealment mechanism
The randomisation sequence will be concealed using
several measures including using an automated random-
isation system and restricting access to the randomisa-
tion sequence. The randomisation sequence will be
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram
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saved in a restricted section of the trial master file which
will only be accessible by statisticians and not those who
enrol or assign interventions.
Study drug
Study drug description
Simvastatin is a HMG-CoA reductase inhibitor which
also has anti-inflammatory activity. The comparator is
a matched placebo tablet with no active ingredient.
Placebo is used as a comparator because of the lack of
any preventative pharmacotherapy demonstrated to be
beneficial for this condition. The study drug will be in
the form of tablet which will be taken orally or
through a feeding tube (if placed) for 4 days before
surgery and for up to 7 days post surgery. The
duration of the therapy is based on the anti-inflamma-
tory effects of simvastatin 80 mg in the human inhaled
LPS model of pulmonary injury [12] and the reduction
in pulmonary inflammation in the single-centre
proof-of-concept study in oesophagectomy patients
[14] utilising this dose and duration. The study drug
will be dispersed in 10–20 mL of water when adminis-
tered via the feeding tube.
Study drug supply
Patient drug packs will be prepared by Victoria Pharma-
ceuticals. Simvastatin 40 mg or matching placebo tablets
will be packaged in a white, opaque, high-density poly-
ethylene plastic container which will be sealed with a
tamper-evident seal and labelled in compliance with ap-
plicable regulatory requirements. Each container will
contain 40 tablets of study drug for the treatment of one
patient for 20 days (which includes 9 days’ coverage to
allow for surgical delays and drug wastage by accident).
All trial drugs will be packaged identically and identified
only by a unique medication pack identification number
in accordance with the study randomisation sequence.
Study drug termination
The study drug will be discontinued if any one of the
following conditions is met, prior to the maximum treat-
ment period (11 days from the start of study drug):
1. Study-drug-related AE:
a) CK > 10 times the ULN of the local laboratory
range
b) ALT/AST > 5 times the ULN of the local
laboratory range
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist
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2. Development of a clinical condition requiring
immediate treatment with a statin or other drugs
which interact with statins
3. Discontinuation of active medical treatment
4. Patient’s request for withdrawal from the study
5. Decision by the attending clinician that the study
drug should be discontinued on safety grounds
6. Discharge from hospital
7. Change of type of surgery
8. Death
Withdrawal of consent post randomisation
Patients may withdraw or be withdrawn from the trial at
any time without prejudice. Data recorded up to the
point of withdrawal will be included in the trial analysis,
unless consent to use their data has also been with-
drawn. If a patient requests termination of the trial drug
during the treatment period, the drug will be stopped
but the patient will continue to be followed-up as part of
the trial. If a patient withdraws consent during trial
treatment, the trial drug will be stopped but permission
will be sought to access medical records for data related
to the trial. If a patient wishes to withdraw from the trial
after completion of trial treatment, permission to access
medical records for trial data will be sought.
Intervention adherence
Adherence to the study drug will be monitored by re-
cording the number of tablets returned at the end of the
treatment period which will be used to calculate the
number of doses administered. The patients will also
maintain a diary record of self-administration prior to
admission for their surgery. Patients will be withdrawn
from the study if they have taken no study drug at all
prior to surgery.
Blinding
This is a double-blind, placebo-controlled trial, and pa-
tients, clinicians and the study team will be blinded to
each patient’s treatment allocation. All trial drugs,
whether simvastatin or placebo, will be packaged identi-
cally and identified only by a unique, medication-pack
identifier.
Emergency unblinding
Emergency unblinding can be requested by a PI or des-
ignated investigator on safety grounds, or if the treat-
ment decision for a patient could be influenced by the
knowledge of what the patient is taking as part of the
trial. If the PI or designated investigator decides that
there is justification to unblind a patient, emergency
unblinding can be performed via the randomisation sys-
tem. In the event of failure of the online system, back-up
manual unblinding will be performed by the clinical
trials pharmacist between 9 a.m. and 5 p.m. or the
on-call pharmacist out of hours in the Royal Victoria
Hospital, Belfast. In the event that unblinding occurs,
the patient may discontinue the study drug but will re-
main in the trial unless they decide to withdraw. Where
unblinding has occurred, this should be fully docu-
mented by the site and the Clinical Trials Unit (CTU)
informed.
Data collection
To ensure that accurate, complete and reliable data are
collected, the CTU will provide training to site staff in
the format of investigator meetings and/or site-initiation
visits. Data will be collected through electronic data cap-
ture (EDC). Data will be obtained through patient’s hos-
pital notes, hospital laboratory records and image
records. All data for an individual patient will be col-
lected by the PI or their delegated nominees and re-
corded in the EDC database for the study except 90-day
follow-up data. For the economic evaluation, HRQoL
will be measured by the EQ-5D-5 L at baseline and at
90 days post surgery. Resource use data will be collected
via the questionnaire administered at 90 days post sur-
gery. The patients’ confidentiality will be maintained and
will not be made publicly available to the extent permit-
ted by the applicable laws and regulations. On comple-
tion of the trial, the trial master file will be archived by
the CTU and the investigator site file and study data will
be archived by the PI at each site according to the ap-
plicable regulatory requirements.
Follow-up visits and procedures
All survivors will be followed up at 90 days after surgery.
HRQoL will be measured using the EQ-5D-5 L adminis-
tered at baseline and at 90 days post surgery. Health and
social care resource use will be collected via a question-
naire at 90 days post surgery. Where the patient has
been discharged from hospital, questionnaires will be ad-
ministered via post. If questionnaires are not returned, a
maximum of two telephone contacts will be made to the
study participant; the first call will check that the ques-
tionnaire has been received and the participant is happy
to complete it. If necessary, a second copy of the ques-
tionnaire will be sent. In the event of non-return, one
further telephone contact will be made and the health
economic data collected over the telephone where pos-
sible. To minimise the risk of causing distress by con-
tacting relatives of patients who have since deceased, the
CTU will contact the patient’s GP to ascertain the pa-
tient survival status prior to any contact being made.
Safety monitoring and adverse event (AE) reporting
The AEs will be defined as stipulated by the Medicine
and Healthcare Products Regulatory Agency (MHRA)
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Good Clinical Practice Guide 2012 and reported as per
guidance. The PI or designee will record all directly ob-
served AEs and those reported by the patient. In
addition, the patient will be asked about AEs up to 28
days post surgery or on discharge from hospital if earlier.
The PI or designee must assess all AEs for seriousness,
causality, severity and if the AE is related to the study
drug for expectedness. All reportable AEs should be re-
corded in the patient’s medical notes and on the AE
form within the EDC.
Prevention HARP-2 is recruiting a population that is
already undergoing a major surgical intervention, it is
expected that many of the participants will experience
AEs. Events that are expected in this population (i.e.
events that are in keeping with the patient’s underlying
medical or surgical condition) should not be reported as
AEs or SAEs. Death which is ascertained to be not re-
lated to surgical complications or progression of the pri-
mary or secondary outcomes should be reported as a
SAE. SAEs will be evaluated by the PI for causality (i.e.
their relationship to study drug) and expectedness. An
adverse reaction (AR) is an AE which is related to the
administration of the study drug. If any AEs are related
to the study drug (i.e. are ARs) they must be reported on
the AE form within the EDC.
The following are ARs which are expected and must
be reported on the AE form within the EDC: CK > 10
times the ULN, ALT/AST > 5 times the ULN.
The following serious adverse reaction is expected and
must be reported on the SAE form within the Case Re-
port Form (CRF): need for renal replacement therapy in
patients with CK > 10 times the ULN.
All SAEs should be reported within 24 h of becoming
aware of their occurrence. They should be reported to
the CTU and the chief investigator (CI), who will inform
the sponsor and regulatory authorities.
Statistical analysis plan
This is a randomised, placebo-controlled, parallel-group,
superiority trial. Intention-to-treat analysis (ITT) will be
followed for the primary analysis and patients will be
analysed according to the treatment that they were ran-
domised to, disregarding the actual treatment received.
Patients should have received at least one dose pre sur-
gery for inclusion into the analysis. Patients who did not
proceed to the planned surgery will also be excluded
from the final analysis. A per-protocol analysis will be
performed in addition to the ITT analysis.
The primary outcome measure will be compared be-
tween treatment groups using a chi-square test. We will
also report each primary outcome component separately.
A secondary analysis will involve a logistic regression
model, with the dependent variable as composite end-
point/no composite endpoint within 7 days and the
independent variables as treatment, centre, type of sur-
gery and age as a covariate. An odds ratio measuring the
treatment effect and its 95% confidence interval will be
reported. Other categorical outcomes will be analysed
using logistic regression models, with treatment group
as an independent variable along with centre, type of
surgery and age as a covariate. The summary statistics
will be based on proportions and the 95% confidence
interval. Continuous outcomes will be analysed using
linear regression models, with treatment group as an in-
dependent variable and terms for centre, type of surgery
and age in the model. Difference in treatment will be
based on adjusted mean estimates and 95% confidence in-
tervals. Time-to-event data will be analysed using a
log-rank test. Any patients who have not experienced an
event at the time point of interest or withdrawn will be
censored. The proportion experiencing an event over time
will be illustrated using a Kaplan-Meier curve for each of
the treatment groups. The p values and a hazard ratio with
its 95% confidence interval from a Cox proportional haz-
ards model will also be presented. The proportional haz-
ard assumption across treatment arms will be checked
graphically using a log-cumulative hazard plot.
Baseline characteristics, follow-up measurements and
safety data will be described using appropriate descrip-
tive summary measures depending on the scale of meas-
urement and distribution.
Subgroup analyses will use a statistical test for inter-
action and will be reported using 99% confidence interval.
Four subgroup analyses are pre-specified, stratifying by
chemotherapy prior to surgery (yes/no), type of surgery
(oesophagectomy, lobectomy, pneumonectomy), surgical
technique (minimally invasive/hybrid/open) and duration
of OLV (≤ 120 min and > 120 min [20]). We shall also in-
vestigate subgroups based on smoking status.
An interim analysis will also be conducted to analyse
efficacy and safety parameters. This will occur when ap-
proximately 50% of the planned number of patients to
be randomised have completed day 28 assessment or
have been discharged from hospital, whichever is sooner.
In relation to efficacy, a chi-square test will be applied
with a p value < 0.001 according to the Haybittle-Peto
stopping rule. For safety, the acute kidney injury data
will be presented alongside other safety data.
Every effort will be made to minimise missing baseline
and outcome data in this trial. The level and pattern of
the missing data in the baseline variables and outcomes
will be established by forming appropriate tables and the
likely causes of any missing data will be investigated.
This information will be used to determine whether the
level and type of missing data have the potential to
introduce bias into the analysis results for the proposed
statistical methods, or substantially reduce the precision
of estimates related to treatment effects. If necessary,
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these issues will be dealt with using multiple imputation
or Bayesian methods for missing data as appropriate. A
detailed statistical analysis plan will be produced prior to
the end of patient recruitment and database lock.
Health economic evaluation
A within-trial cost-utility analysis will be conducted to as-
sess the cost-effectiveness of simvastatin compared to pla-
cebo at 90 days’ follow-up (post-surgery). A health service
perspective will be adopted as recommended by the Na-
tional Institute for Health and Care Excellence (NICE)
[37]. The health outcome for the analysis will be
quality-adjusted life years (QALYs) and these will be cal-
culated for each patient using responses on the EQ-5D-5
L. Patient-level healthcare resource use (of primary, com-
munity and social care services) will be obtained from the
trial CRF and the self-completed patient questionnaires,
and combined with publicly available unit costs to esti-
mate costs for each participant. It will not be necessary to
discount costs and outcomes given the duration of
follow-up. Standard methods will be used to explore and
display uncertainty in the cost-effectiveness data including
scatter plots on the cost-effectiveness plane and
cost-effectiveness acceptability curves. Sensitivity analyses
will be performed to assess the robustness of the
cost-effectiveness results to changes in key parameters. A
detailed health economic analysis plan will be finalised
prior to commencing the analysis.
Trial organisation/oversight
Participant safety will be monitored by an independent Data
Monitoring and Ethics Committee through regular review
of AEs. A Trial Steering Committee will provide trial over-
sight. The members of the Committees will be experienced
in clinical trials and will be from a variety of backgrounds
including clinical trialists, a statistician and a lay public
member. All protocol amendments will be implemented
only after approval from the sponsor, Ethics Committee and
MHRA. The trial will comply with the principles of GCP,
the requirements and standards set out by the EU Directive
2001/20/EC and the applicable regulatory requirements in
the UK, the Medicines for Human Use (Clinical Trials) Reg-
ulations 2004 and subsequent amendments and the Re-
search Governance Framework. It will also adhere to the
SOPs of the NICTU. The trial will be subject to independ-
ent audit initiated by the sponsor, MHRA and trial monitor-
ing as per NICTU monitoring SOPs.
Dissemination
The results of the trial will initially be reported to the
trial collaborators and the findings will be presented at
national and international meetings with open-access ab-
stracts on-line, e.g. the American Thoracic Society an-
nual meeting. The findings will be published in
high-quality, peer-reviewed, open-access (via PubMed)
journals in accordance with the open-access policies and
make the results readily accessible to the public, health-
care professionals and scientists. A lay person’s summary
of the principal findings of the results will be sent to all
patients involved in the study at their request. In
addition, a lay person’s summary will be sent to local
and national patient support and liaison groups (e.g.
ICU Steps, hospital patient groups). A report of the
study findings will be sent to the INVOLVE registry.
Where appropriate, research details will also be posted on
institutional websites available to the general public. In
addition, the most significant results will be communi-
cated to the public through press releases. The sponsor
and funder do not have any involvement in the trial meth-
odology, data collection, analysis and dissemination.
Trial status and summary
Prevention HARP 2 is a UK multi-centre, randomised
trial comparing peri-operative simvastatin 80 mg and
placebo in preventing PPC and MI in adult patients
undergoing OLV for oesophagectomy, lobectomy and
pneumonectomy. The current protocol version is v7.0
dated 7 December 2017. The recruitment to this trial
commenced in November 2016 and is expected to
complete in July 2020.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*. (PDF 86 kb)
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